Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NP-G2-044 |
Synonyms | |
Therapy Description |
NP-G2-044 is a small molecule that inhibits fascin, resulting in aberrant actin cytoskeleton reorganization, and potentially resulting in decreased tumor cell migration and metastasis (PMID: 27071719). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NP-G2-044 | NP G2 044 | NP-G2-044 is a small molecule that inhibits fascin, resulting in aberrant actin cytoskeleton reorganization, and potentially resulting in decreased tumor cell migration and metastasis (PMID: 27071719). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
NCT05023486 | Phase Ib/II | NP-G2-044 NP-G2-044 + unspecified PD-L1 antibody | NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |